Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron Plus REBETOL Long-Term Follow-Up in Pediatric Hepatitis C
NCT00761735Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2007
- Primary completion
- Jan 2013
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b in hepatitis C (HCV), sponsored by Merck & Co.. Started Jul 2007; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00761735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00761735.